Form 4: Apellis Pharmaceuticals' General Counsel, David O. Watson, Reports Stock Transactions

David O. Watson, General Counsel of Apellis Pharmaceuticals, reported the transfer and sale of company stock, including transactions involving trusts and custodial accounts.

Summary

• On March 4, 2025, David O. Watson, General Counsel of Apellis Pharmaceuticals, transferred 6,667 shares of common stock from the Watson Education Trust to a custodial account for his minor son at no cost.
• He also gifted 6,667 shares to the custodial account.
• On March 5, 2025, Watson sold 5,569 shares of common stock at a price of $25.1013 per share.
• Following these transactions, Watson directly owns 138,730 shares and indirectly owns shares through the Watson Education Trust (0 shares), a custodial account for his son (10,000 shares), and The David O. Watson Irrevocable Trust of 2023 (70,136 shares).

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel and their potential alignment with shareholder interests.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the actions of a key company officer.
• The sale of shares could potentially exert downward pressure on the stock price, although the volume is relatively small.

Key Dates